Insulin sentizier for PCOS women undergoing ICSI
Not Applicable
Not yet recruiting
- Conditions
- Fertility-femalePCOS infertile womenNutritional, Metabolic, Endocrine
- Registration Number
- PACTR201308000579176
- Lead Sponsor
- Hassan Aly Hassan Elmeghraby
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 220
Inclusion Criteria
Patients with PCSO as defined by Androgen excess-PCOS Society Task Force (2009)
Exclusion Criteria
Diabetes
Hypertension
Intrauterine pathology
Cholclate cyst
Morbid obesity (BMI >35)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain pioglitazone's effects on insulin resistance in PCOS patients undergoing ICSI?
How does pioglitazone hydrochloride compare to metformin in improving ICSI outcomes for PCOS women with metabolic syndrome?
Which biomarkers correlate with response to PPAR-γ agonists in PCOS patients with endocrine infertility undergoing ICSI?
What are the potential adverse events of pioglitazin in PCOS women using antagonist protocols for ICSI?
Are there combination therapies involving pioglitazone that enhance ovarian response in PCOS patients undergoing ICSI?